StocksMedium•6 November 2026•
1 min read
Ultragenyx to Cut 20% of Workforce and Terminate Drug Programs
Key Facts
1Ultragenyx plans to reduce its workforce by approximately 20%, affecting about 250 positions by the end of 2026.
2The company expects to incur approximately $25 million in severance and related charges in the fourth quarter.
Ultragenyx plans to reduce its workforce by approximately 20%, affecting about 250 positions by the end of 2026. Medical Daily reported that the company is terminating its GTX-102 and UX701 gene therapy programs for Angelman and Wilson diseases to streamline operations following unsuccessful clinical trial outcomes.
The company expects to incur approximately $25 million in severance and related charges during the fourth quarter. RARE closed at $15.57 on November 5, 2026, having reached a session low of $15.49 on that date.